Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Sherry Aulin - CFO Ian Mortimer - President and CEO Dr. Chris Kenney - CMO Dr. Chris Von Seggern - Chief Commercial Officer Conference Call Participants Tessa Romero - J.P. Morgan Paul Matteis - Stifel Brian Abrahams - RBC Capital Markets Andrew Tsai - Jefferies Paul Choi - Goldman Sachs Joseph Thome - TD Cowen Danielle Brill - Raymond James Laura Chico - Wedbush Securities Mohit Bansal - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-36687 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in its Charter) (State or other ju ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Sherry Aulin - CFO Ian Mortimer - President and CEO Dr. Chris Kenney - CMO Dr. Chris Von Seggern - Chief Commercial Officer Conference Call Participants Paul Matteis - Stifel Brian Abrahams - RBC Capital Markets Tessa Romero - J.P. Morgan Andrew Tsai - Jefferies Joseph Thome - TD Cowen Rudy Li - SVB Danielle Brill - Raymond James Laura Chico - Wedbush Securities Elaine Kim - Cantor Fitzgerald ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-36687 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in its Charter) Canada 98-0661854 ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Sherry Aulin - CFO Ian Mortimer - President and CEO Chris Kenney - CMO Chris Von Seggern - CCO Conference Call Participants Brian Abrahams - RBC Capital Markets Tessa Romero - JPMorgan Paul Choi - Goldman Sachs Joseph Thome - TD Cowen Andrew Tsai - Jefferies Rudy Li - SVB Securities Laura Chico - Wedbush Rohit Bhasin - Needham & Company Operator Ladies and gentlemen, thank you for standing ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36687 XENON PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) | Canada | 98-0661854 | | --- | --- | | (Stat ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET Company Participants Sherry Aulin - Chief Financial Officer Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Chris Von Seggern - Chief Commercial Officer Conference Call Participants Paul Matteis - Stifel Andrew Tsai - Jefferies Tessa Romero - JP Morgan Brian Abrahams - RBC Capital Markets Madhumita Yennawar - SVB Securities Laura Chico - Wedbush Yatin Suneja - Guggen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-36687 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in its Charter) Canada 98-066 ...

Corporate Overview A U G U S T 2 0 2 2 NASDAQ: XENE www.xenon-pharma.com Forward Looking Statement/Safe Harbor This slide presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact could be deem ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Sherry Aulin - Chief Financial Officer Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Chris Von Seggern - Chief Commercial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Tessa Romero - JPMorgan Marc Goodman - SVB Andrew Tsai - Jefferies David Hoang - SMBC Lachlan Hanbury - William Blair Operator Good afternoon and welco ...